ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2019
Incidence and mortality of thyroid cancer in China, 2008
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Implications of five endoscopic and conventional open surgery on lateral neck dissection outcomes in patients with papillary thyroid carcinoma: a network meta-analysis and systematic review.Surgical endoscopy · 2025Pooled it
- Prevention of hypoparathyroidism: A step-by-step near-infrared autofluorescence parathyroid identification method.Frontiers in endocrinology · 2023Trial
- Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection.Annals of medicine · 2026Article
- Oncogenic role of LncRNA DLEU2 in thyroid cancer through a NAT10/USP39 regulatory axis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Microbial biomarkers and sex-associated gut microbiota characteristics of thyroid cancer.BMC cancer · 2025Article
- Gut microbiome versus thyroid cancer: Association and clinical implications (Review).Oncology letters · 2025Review
- Article
- BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.World journal of surgical oncology · 2024Article
- A new strategy of using low-dose caffeic acid carbon nanodots for high resistance to poorly differentiated human papillary thyroid cancer.Journal of nanobiotechnology · 2024Article
- Thyroid cancer trends in China and its comparative analysis with G20 countries: Projections for 2020-2040.Journal of global health · 2024Observational
- Article
- Article
- LRG1 predicts the prognosis and is associated with immune infiltration in thyroid cancer: a bioinformatics study.Endocrine connections · 2024Article
- GPX4 inhibits apoptosis of thyroid cancer cells through regulating the FKBP8/Bcl-2 axis.Cancer biomarkers : section A of Disease markers · 2024Article
- Exploring the oral-gut microbiota during thyroid cancer: Factors affecting the thyroid functions and cancer development.Food science & nutrition · 2023Review
- Sensitivity to thyroid hormone indices are associated with papillary thyroid carcinoma in Chinese patients with thyroid nodules.BMC endocrine disorders · 2023Article
- Landscape of gene mutation in Chinese thyroid cancer patients: Construction and validation of lymph node metastasis prediction model based on clinical features and gene mutation marker.Cancer medicine · 2023Article
- Assessment of radiation exposure and public health before and after the operation of Sanmen nuclear power plant.Frontiers in public health · 2023Article
- The analysis and validation of the prediction value of conventional and contrast-enhanced ultrasonography forGland surgery · 2022Article
- LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the incidence and mortality rates of thyroid cancer (TC) in China from 2008 to 2012.
methodsIncident and death cases of TC were retrieved from the National Central Cancer Registry (NCCR) database collecting from 135 cancer registries in China during 2008-2012. The crude incidence and mortality rates of TC were calculated by area (urban/rural), region (eastern, middle, western), gender and age group (0, 1-4, 5-9, …, 85+). China census in 2000 and world Segi's population were applied for age-standardized rates. Joinpoint (Version 4.6.0.0) model was used for time-trend analysis.
resultsThe crude incidence rate of TC was 7.56/100,000 which ranked the seventh in overall cancers. The age-standardized incidence rates by China population (ASIRC) and by World population (ASIRW) were 6.25/100,000 and 5.52/100,000, respectively. The crude mortality of TC in China was 0.52/100,000. The age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 0.34/100,000 and 0.32/100,000, respectively. Incidence and mortality rates of TC were higher in females than in males and higher in urban areas than in rural areas. Eastern areas had the highest incidence followed by middle and western areas. TC incidence increased dramatically after age of 15 years, then peaked at 14.08/100,000 in the group of 50-54 years and finally decreased sharply after 55 years old. TC mortality increased with age in population, reaching the peak of 5.09/100,000 in sub-population aged 85 years or older. TC incidence increased by 4.73 times from 2.40/100,000 in 2003 to 13.75/100,000 in 2012 with an average annual increase of 20%, while TC mortality only increased slightly around 0.32/100,000 from 0.26/100,000 to 0.36/100,000.
conclusionsAppropriate targeted prevention, early detection and treatment programs can be carried out to curb the rapid growth trend of TC and control the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.